| Revenue growth | 23.6% YoY in FY26; 32.8% YoY in Q4 FY26. |
|---|---|
| Margins | Resilient; EBITDA margins held in 19%-20% band for 4 years. |
| Demand visibility | Strong; 100%+ net revenue retention and broadening customer base. |
| Management confidence | High; entering FY27 with confidence and strong pipeline. |
Growth
FY26 revenue up 23.6% in INR; Q4 revenue up 32.8% YoY to INR 10,034M. $1M+ clients grew 29% to 53.
Outlook
Entering FY27 with momentum; focus on GenAI-native workflows and integrating recent BioPharm acquisition. Final dividend of ₹2.25 proposed.
Risks
Higher non-cash charges impacting reported profits; potential macro-driven cycle-time compression in pharma spend.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹608.95
- Market cap
- ₹14,670 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 57.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Earnings Call Transcript: Key Takeaways
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Investor Presentation: Key Takeaways
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Q1 FY27 Results: Net Profit ₹116.2 Cr, Down 0.2% YoY
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹116.2 Cr · -0.2% YoY
Indegene Earnings Call: Key Takeaways
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.